

Agreed Haematology Chemotherapy Regimens (Adults)

Version 18 – updated December 2017

Regimen	ASPH	SASH	RSCH
Acute Myeloid Leukaemia			
AIDA	√	√	√
Azacitidine	√	√	√
Cytarabine subcutaneous	√	√	√
High dose Cytarabine	√	√	√
DA	√	√	√
FLAG	√	√	√
FLAG-IDA	√	√	√
Lenalidomide for MDS	√	√	√
MIDAC	√	√	√
Tretinoin (All Trans Retinoic Acid)	√	√	√
Myeloproliferative/dysplastic disorders (inc. CML and CMML)			
Anagrelide	√	√	√
Azacitidine	√	√	√
Bosutinib	√	√	√
Busulfan	√	√	√
Dasatinib	√	√	√
Etoposide	√	√	√
Hydroxycarbamide	√	√	√
Imatinib	√	√	√
Interferon alfa	√	√	√
Nilotinib	√	√	√
Ponatinib	√	√	√
Ruxolitinib	√	√	√
Vinblastine-based regimen for LCH	√	√	√
Hairy Cell Leukaemia			
Cladribine	√	√	√
Pentostatin	√	√	√
Multiple Myeloma			
Bendamustine-Thal-Dex (BDT)	√	√	√
Bortezomib + Dex +/- Cyclophos (CVD)	√	√	√
Bortezomib + Dex +/- Thalidomide (VTD)	√	√	√
Carfilzomib & Dex	√	√	√
CTD / CTDa	√	√	√
Cyclophosphamide weekly	√	√	√
Pulsed Dexamethasone	√	√	√
DT-PACE	√	√	√
LCD	√	√	√
MPT	√	√	√
PAD	√	√	√
Panobinostat + Bortezomib	√	√	√
Pomalidomide	√	√	√
Thalidomide single agent	√	√	√

Reason for Update: FPH column removed; LCH regimen added, Venetoclax, Nivolumab and AL amyloidosis regimens added; Obinutuzumab-Benda & MATRix added

Prepared by: S Taylor

Version: 19

Supersedes: Version 18

AL Amyloidosis			
CVD (low dose)	√	√	√
CVD (intermediate dose)	√	√	√
CVD (21 day cycle)	√	√	√
Hodgkin's Disease			
ABVD	√	√	√
BEACOPP-14	√	√	√
ChIVPP	√	√	√
Nivolumab	√	√	√
Non Hodgkin's Lymphoma / Chronic Lymphocytic Leukaemia			
Alemtuzumab	√	√	√
Chlorambucil +/- Rituximab for CLL	√	√	√
Chlorambucil +/- Rituximab for LGL	√	√	√
High dose Methotrexate & HD Cytarabine	√	√	√
High dose Methotrexate for CNS prophylaxis	√	√	√
Intrathecal MTX +/- Cytarabine +/- Hydrocortisone	√	√	√
High Dose Methylprednisolone	√	√	√
Ibrutinib	√	√	√
MATRix	√	√	√
Obinutuzumab-Bendamustine	√	√	√
Obinutuzumab-Chlorambucil	√	√	√
Pixantrone	√	√	√
R-Bendamustine for CLL	√	√	√
R-Bendamustine-90 for lymphoma	√	√	√
R-CHOP	√	√	√
R-CVP	√	√	√
R-FC	√	√	√
R-GCVP	√	√	√
R-Idelalisib	√	√	√
R-Methylprednisolone	√	√	√
R-Maxi-CHOP and HD Cytarabine (Nordic)	√	√	√
Rituximab IV maintenance	√	√	√
Rituximab SUBCUTANEOUS maintenance	√	√	√
Venetoclax	√	√	√
Second Line and Salvage Lymphoma (Hodgkin's Disease and NHL)			
Brentuximab	√	√	√
ESHAP	√	√	√
GDP	√	√	√
Gem-P	√	√	√
IVE	√	√	√
mini-BEAM / mini-LEAM	√	√	√
Rituximab IV monotherapy	√	√	√
Peripheral Blood Stem Cell Mobilisation			
GCSF post salvage (use protocol provided by tertiary centre performing transplant)	√	√	√
Cyclo/Mesna/GCSF (use protocol provided by tertiary centre performing transplant)	√	√	√

Reason for Update: FPH column removed; LCH regimen added, Venetoclax, Nivolumab and AL amyloidosis regimens added; Obinutuzumab-Benda & MATRix added
Version: 19

Prepared by: S Taylor

Supersedes: Version 18